Portage Biotech (Portage Biotech) Cash-to-Debt : 19.42 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Portage Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Portage Biotech's cash to debt ratio for the quarter that ended in Dec. 2023 was 19.42.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Portage Biotech could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Portage Biotech's Cash-to-Debt or its related term are showing as below:

PRTG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.86 Med: 888.95 Max: No Debt
Current: 19.42

During the past 13 years, Portage Biotech's highest Cash to Debt Ratio was No Debt. The lowest was 0.86. And the median was 888.95.

PRTG's Cash-to-Debt is ranked better than
64.07% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs PRTG: 19.42

Portage Biotech Cash-to-Debt Historical Data

The historical data trend for Portage Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Portage Biotech Cash-to-Debt Chart

Portage Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

1.71

0.88

1.54

No Debt

Portage Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	26.01	12.05	19.42

Competitive Comparison of Portage Biotech's Cash-to-Debt

For the Biotechnology subindustry, Portage Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Portage Biotech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portage Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Portage Biotech's Cash-to-Debt falls into.

Portage Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Portage Biotech's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Portage Biotech had no debt ⁽¹⁾.

Portage Biotech's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.341	/	(0.05	+	0.225)
	=	19.42

Portage Biotech (NAS:PRTG) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Portage Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Portage Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Portage Biotech (Portage Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110

Website

https://www.portagebiotech.com

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.